{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:27:19Z","timestamp":1790245639620,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.urolonc.2004.12.012","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T03:50:48Z","timestamp":1118807448000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer\u2606"],"prefix":"10.1016","volume":"23","author":[{"given":"Eric","family":"Winquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2004.12.012_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2004.12.012_bib2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0959-8049(02)00166-1","article-title":"Farnesyl transferase inhibitors as anticancer agents","volume":"38","author":"Haluska","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2004.12.012_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000052494","article-title":"Bladder cancer. I. Molecular and genetic basis of carcinogenesis","volume":"39","author":"Brandau","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib4","first-page":"241","article-title":"Ras and human tumors","volume":"3","author":"Rodenhuis","year":"1992","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib5","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2174\/1381612023393071","article-title":"Agents targeting ras signaling pathway","volume":"8","author":"Dancey","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.urolonc.2004.12.012_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000421-199812000-00010","article-title":"A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme","volume":"21","author":"Larner","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1006\/gyno.2002.6647","article-title":"A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer","volume":"85","author":"Bailey","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib8","first-page":"3071","article-title":"Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies","volume":"6","author":"Hudes","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2004.12.012_bib9","first-page":"1065","article-title":"A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer","volume":"8","author":"Hahn","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2004.12.012_bib10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.leu.2402832","article-title":"The farnesyltransferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells","volume":"17","author":"Bolick","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.urolonc.2004.12.012_bib11","first-page":"4919","article-title":"Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I","volume":"59","author":"Sun","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2004.12.012_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1124\/jpet.102.042952","article-title":"c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor","volume":"304","author":"Russo","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.urolonc.2004.12.012_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2210-2-2","article-title":"The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution","volume":"2","author":"Megnin-Chanet","year":"2002","journal-title":"BMC Pharmacol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib14","first-page":"4947","article-title":"Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2004.12.012_bib15","first-page":"1871","article-title":"A phase I trial of the farnesyl transferase inhibitor SCH66336","volume":"60","author":"Adjei","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2004.12.012_bib16","first-page":"156a","article-title":"Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule","volume":"18","author":"Hurwitz","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2001.19.4.1167","article-title":"Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors","volume":"19","author":"Eskens","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib18","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0959-8049(02)00379-9","article-title":"Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours","volume":"38","author":"Awada","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2004.12.012_bib19","unstructured":"National Cancer Institute. SEER Cancer Statistics Review, 1975\u20132000. Available at: http:\/\/seer.cancer.gov\/csr\/1975_2000\/results_single\/sect_01_table.01.pdf. Accessed January 6, 2005."},{"key":"10.1016\/j.urolonc.2004.12.012_bib20","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib21","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0022-5347(01)65459-4","article-title":"Paclitaxel in advanced urothelial carcinoma","volume":"156","author":"Dreicer","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib22","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2001.19.12.3018","article-title":"Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract","volume":"19","author":"Meluch","year":"2001","journal-title":"J Clin Oncol 15"},{"key":"10.1016\/j.urolonc.2004.12.012_bib23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1081\/CNV-120003536","article-title":"Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer","volume":"20","author":"Bellmunt","year":"2003","journal-title":"Cancer Invest"},{"key":"10.1016\/j.urolonc.2004.12.012_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s002400050050","article-title":"Molecular alterations in bladder cancer","volume":"26","author":"Orntoft","year":"1998","journal-title":"Urol Res"},{"key":"10.1016\/j.urolonc.2004.12.012_bib25","first-page":"57","article-title":"Molecular genetics of bladder cancer","volume":"75","author":"Knowles","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0304-3835(96)04372-8","article-title":"Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors","volume":"107","author":"Vageli","year":"1996","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2004.12.012_bib27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1023\/A:1008313232381","article-title":"Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units","volume":"10","author":"Petit","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib28","unstructured":"http:\/\/ctep.info.nih.gov\/reporting\/index.html. Accessed January 6, 2004."},{"key":"10.1016\/j.urolonc.2004.12.012_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2004.12.012_bib30","first-page":"599","article-title":"Multinomial phase II trial designs","volume":"20","author":"Freidlin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2004.12.012_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.urolonc.2004.12.012_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000074531","article-title":"The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2","volume":"49","author":"Wang","year":"2003","journal-title":"Exp Chemother"},{"key":"10.1016\/j.urolonc.2004.12.012_bib33","first-page":"219","article-title":"Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells","volume":"2","author":"Nakajima","year":"2003","journal-title":"Mol Cancer Ther"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143904002728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143904002728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:51:59Z","timestamp":1761040319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143904002728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S1078143904002728"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2004.12.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer\u2606","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2004.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}